New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
Go back to New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)| Merck & Co. (NYSE: MRK) | Delayed: 152.34 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $152.34 | 52 Week High | $65.46 | |||
| Open | $152.34 | 52 Week Low | $47.97 | |||
| Day High | $152.34 | P/E | 103.63 | |||
| Day Low | $152.34 | EPS | $1.47 | |||
| Volume | 1,990 | |||||
